Phase 2 N=14 Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
Recurrent Melanoma · Stage III Skin Melanoma · Stage IV Skin Melanoma
Primary: Response — 11 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
Unresectable Malignant Neoplasm · Melanoma · Metastatic Melanoma
Primary: Resectability Rate — 8; 2 Participants
Phase 2 N=60 Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
Stage III Melanoma · Stage IV Melanoma · Unresectable Melanoma
Primary: Percentage of Participants With Progression-free Survival at 6 Months — 68 percentage of participants
Phase 2 N=30 Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Acral Lentiginous Malignant Melanoma · Recurrent Melanoma · Stage IIIA Melanoma
Primary: Objective Response Rate — 1; 3; 14; 7 participants
Phase 2 N=24 Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
Melanoma · Skin Cancer · Cancer
Primary: Overall Objective Response (Complete Response or Partial Response) — 2; 2; 15 participants
Phase 3 N=270 A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
Melanoma
Primary: Progression Free Survival (PFS) — 122; 125 days — p=0.492
Phase 2 N=105 Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Primary: Progression Free Survival (PFS) at 18-month — 65.5; 66.3 Percentage of participants
Phase 2 N=101 Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma
Cancer · Melanoma
Primary: Progression Free Survival (PFS) — 148; 82 days — p=0.068
Phase 2 N=76 Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
Intraocular Melanoma · Melanoma (Skin)
Primary: Percentage of Participants With Immune-related Adverse Events (irAEs) — 80.0; 72.0; 65.4 Percentage of participants
Phase 2 N=49 Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
Melanoma (Skin)
Primary: 9-week Progression-free Survival Rate — 0.44 proportion of patients
Phase 2 N=13 Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Melanoma (Skin)
Primary: Tumor Response as Measured by RECIST Criteria — 6; 7 Participants
Phase 2 N=169 Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Stage IIIC Cutaneous Melanoma AJCC v7 · Stage IV Cutaneous Melanoma AJCC v6 and v7 · Unresectable Melanoma
Primary: Overall Survival (OS) — 20.4; 20.1 months — p=0.383
Phase 2 N=95 Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
Melanoma (Skin)
Primary: Progression-free Survival at 6 Months — 32.8; 56.1 % of patients alive and progression free
Phase 2 N=26 Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
Metastatic Melanoma
Primary: Complete Response — 7; 3 Participants
Phase 3 N=676 MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Melanoma · Metastases
Primary: Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone — 9.95…
Phase 2 N=76 Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Melanoma (Skin)
Primary: Tumor Response Rate, as Measured by RECIST Criteria — 8.8; 25.6 percentage of participants
Phase 2 N=31 Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma
Advanced Melanoma · Unresectable Melanoma
Primary: Overall Response Rate (ORR) — 10 percentage of patients
Phase 2 N=37 Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma
Melanoma
Primary: Best Objective Response Rate (BORR) — 24 percentage of patients
Phase 2 N=52 Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients
Melanoma
Primary: Response to Neoadjuvant Therapy by Therapy Arms: Clinical Response Rates (CR + PR + SD) — 4; 7; 14; 11 Participants
Phase 2 N=26 A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients
Metastatic Melanoma
Primary: Change in Immune-related Overall Response Rate (irORR) — 20 participants
Phase 3 N=502 Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
Melanoma
Primary: Overall Survival (OS) — 11.17; 9.07 Months — p=0.0009
Phase 2 N=39 Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma
Recurrent Melanoma · Stage IIIA Melanoma · Stage IIIB Melanoma
Primary: Number of Subjects With Objective Response(Partial Response and Complete Response) as Measured by RECIST Criteria — 2 participants
Phase 2 N=23 Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma
Melanoma
Primary: Ganglioside Expressed by Tumor Cells (GD2) — 3; 3; 3; 3 Participants
Phase 2 N=23 Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation
Melanoma
Primary: Percentage of Participants With Relapse Free Survival — 28.6 percentage of participants
Phase 2 N=109 Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
Recurrent Melanoma · Stage IV Melanoma
Primary: Response Rate (Complete and Partial) — 5; 3 Percent of participants
Phase 2 N=24 Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
Metastatic Melanoma · Mucosal Melanoma · Stage IV Cutaneous Melanoma AJCC v6 and v7
Primary: Progression-free Survival (PFS) — 139; 94 days
Phase 2 N=4 Radiation and Combination Immunotherapy for Melanoma
Metastatic Melanoma
Primary: Objective Response Rate (ORR) — 1; 1 Participants
Phase 2 N=32 Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma
Melanoma (Skin)
Primary: Change in Tumor Infiltration by Cluster of Differentiation 8 (CD8) Positive Cytotoxic T Lymphocytes — 289; 104; 955; 428 cells/mL
Phase 1 N=127 Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
Malignant Melanoma
Primary: Number of Participants With an Adverse Event (AE) — 14; 17; 16; 6 Participants
Phase 2 N=1,009 A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
Melanoma
Primary: the Incidence of Highgrade (CTCAE v4.0 Grade 3 or Higher), Treatment Related,Select Adverse Events. — 16; 0; 30; 0 Number of Participants